Results 191 to 200 of about 499,109 (301)

Rapid Identification of New Psychoactive Substances in Letters by LA-APCI-MS. [PDF]

Drug Test Anal
Wesner M, Rämisch H, Besch L, Schmeinck J, Karst U.   +4 more
europepmc   +1 more source

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5‐Year Follow‐Up

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction We aimed to investigate the risks of all‐cause and cause‐specific mortality associated with dose‐dependent benzodiazepine and Z‐drug (BZDR) use in the Finnish population initiating new BZDR use with five‐year follow‐up. Methods Study subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the ...
Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Tero Taiminen, Reijo Sund, Terhi Kurko, Jarmo Hietala, Solja Niemelä   +7 more
wiley   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA)
Hannah Buchbauer, Mazda Adli, Peter Schlattmann, Maximilian Berger, Tom Bschor, Thomas Stamm, Joachim Behr, Roland Ricken, Pichit Buspavanich   +8 more
wiley   +1 more source

Clinical and toxicological epidemiology of intoxications by new psychoactive substances in Reunion Island. [PDF]

Int J Emerg Med
Maillot A, Guyon J, Ma-Tsi-Leong M, Berly L, Weisse F, Mahé A, Roux GL, Nativel F, Daveluy A, Puech B, Marteau A, Leroy M, Plé O, Maillard O, Bastard S, Mete D.   +15 more
europepmc   +1 more source

Using the Danish Administrative Registers to Define Mental Disorders: Potential and Limitations of Using Different Data Sources

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Although the Danish health registers provide rich data for epidemiological mental health research, the comparability of findings is hindered by different definitions of mental disorders across studies. We aimed to describe different approaches taken by researchers to define mental disorders using Danish register data and quantify ...
Natalie C. Momen, Xiaoqin Liu, Ole Köhler‐Forsberg, Bodil Hammer Bech, Oleguer Plana‐Ripoll   +4 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Accuracy of Patient-Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia. [PDF]

Drug Alcohol Rev
Nijmeijer MJ, Smith JL, Weber C, Bens BWJ, Fatovich DM, Greene SL, Schumann JL, Dessauer P, Syrjanen R, Isoardi KZ, Harris K, Alfred S, Tran V, Ter Avest E.   +13 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Analytical Challenges in Detecting New Psychoactive Substances in Anti-Doping: A Proof-of-Concept Involving Pentedrone Metabolite. [PDF]

Drug Test Anal
Kwiatkowska D, Peta B, Grucza K, Łabęcka A, Konarski P, Wojtkowiak K, Grela K, Sytniczuk A, Wicka M.   +8 more
europepmc   +1 more source